Laboratory Correlates of Chemoimmunotherapy with Low-Dose Recombinant Interleukin-2 and Mitomycin C in Patients with Advanced Carcinoma

References

• Rosenberg SA, Lotze MT, Muul JM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose IL 2 alone. N Engl J Med 1987; 316: 889
   PubMed Web of Science ®Google Scholar
• West WH, Taner KW, Yanelli JR. Constant infusion recom- binant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 398
   Google Scholar
• Bukowski RM, Goodman P, Crawford ED. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A southwest oncology group study. J Natl Cancer Inst 1990; 82: 143
   PubMed Web of Science ®Google Scholar
• Clark JW, Smith JW, II, Steis RG. Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res 1990; 50: 7343
   PubMed Web of Science ®Google Scholar
• Wang J, Walle A, Gordon B. Adoptive immunotherapy for stage IV renal cell carcinoma: A novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. Am J Med 1987; 83: 1016
   PubMed Web of Science ®Google Scholar
• Schoof DD, Gramolini BA, Davidson DL. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5007
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Kempf RA, Harel W. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 1988; 6: 409
   PubMed Web of Science ®Google Scholar
• Ettinghausen SE, Moore JG, White DE. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987; 69: 1654
   PubMed Web of Science ®Google Scholar
• Phillips JH, Gemlo BT, Myers WW. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 1987; 5: 1933
   PubMed Web of Science ®Google Scholar
• Thompson JA, Lee DJ, Lindgren CG. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6: 669
   PubMed Web of Science ®Google Scholar
• Eberlein TJ, Rodrick ML, Massaro AF. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans. Caner Immunol Immunother 1989; 30: 145
   PubMed Web of Science ®Google Scholar
• Urba WJ, Steis RG, Longo DL. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res 1990; 50: 185
   PubMed Web of Science ®Google Scholar
• Gemol BT, Palladino MA, Jaffe HS. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5864
   PubMed Web of Science ®Google Scholar
• Kasid A, Director EP, Rosenberg SA. Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 1989; 143: 736
   PubMed Web of Science ®Google Scholar
• Kovacs EJ, Becker SK, Longo DL. Cytokine gene expression during the generation of human lymphokine-activated killer cells: Early induction of interleukin 1 by interleukin 2. Cancer Res 1989; 49: 940
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Favrot MC, Negrier S. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res 1990; 50: 2371
   PubMed Web of Science ®Google Scholar
• Boldt DH, Mills BJ, Gemlo BT. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res 1988; 48: 4409
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Dazzi H, Thatcher N, Moore M. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer 1989; 43: 410
   PubMed Web of Science ®Google Scholar
• Nanbara S, Arinaga S, Akiyoshi T. Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients. Cancer Immunol Immunother 1989; 29: 237
   PubMed Web of Science ®Google Scholar
• Akiyoshi T, Arinaga S, Nanbara S. The effect of interleukin 2 in combination with mitomycin C on advanced cancer. Jpn J Surg 1990; 20: 365
   PubMedGoogle Scholar
• Akiyoshi T, Arinaga S, Karimine N. Effect of recombinant interleukin 2 in combination with mitomycin C or adriamycin on advanced cancer. Proc Am Assoc Cancer Res 1990; 31: 273
   Google Scholar
• Hinuma Onda S.H., Naruo K. Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun 1982; 109: 363
   PubMed Web of Science ®Google Scholar
• Freundlich B, Avdalovic N. Use of Gelatin/plasma coated flasks for isolating human peripheral blood monocytes. J Immunol Meth 1983; 62: 31
   PubMed Web of Science ®Google Scholar
• Taguchi T, Kimoto Y. Clinical application of biological response modifiers: Interleukin 2 (in Japanese). Saishin-Igaku 1987; 42: 325
   Google Scholar
• Silberstein DS, Schoof DD, Rodrick ML. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J Immunol 1989; 142: 2162
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Suda T, Shiozaki H. Role of IL-5 in IL-2-induced eosinophilia: In vivo and in vitro expression of IL-5 mRNA by IL-2. J Immunol 1990; 145: 873
   PubMed Web of Science ®Google Scholar
• Kavacs EJ, Becker SK, Longo D. Lymphokine gene expression during generation of LAK cells. Fed Proc 1987; 46: 925
   Google Scholar
• Bocoli G, Masciulli R, Ruggeri EM. Adoptive immunotherapy of human cancer: The cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res 1990; 50: 5795
   PubMed Web of Science ®Google Scholar
• Mier JE, Vachino G, Van Der Meer JW. Induction of circulating tumor necrosis factor (TNF-α) as the mechanisms for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8: 426
   PubMed Web of Science ®Google Scholar